ID   NOU-1
AC   CVCL_S912
SY   Nou-1; NOU1; AG13904
DR   CLO; CLO_0022358
DR   Coriell; AG13904
DR   Cosmic; 2030480
DR   Wikidata; Q54930929
RX   PubMed=12419584;
RX   PubMed=20944090;
RX   PubMed=28196595;
WW   https://tcpaportal.org/mclp/
CC   Part of: MD Anderson Cell Lines Project.
CC   Sequence variation: Gene deletion; HGNC; 9588; PTEN; Zygosity=Homozygous (PubMed=20944090).
CC   Omics: Protein expression by reverse-phase protein arrays.
CC   Derived from site: In situ; Endometrium; UBERON=UBERON_0001295.
DI   NCIt; C7359; Endometrial adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   52Y
CA   Cancer cell line
DT   Created: 03-02-14; Last updated: 29-06-23; Version: 14
//
RX   PubMed=12419584; DOI=10.1016/S0165-4608(01)00658-6;
RA   Faruqi S.A., Satyaswaroop P.G., LiVolsi V.A., Deger R.B.,
RA   Noumoff J.S.;
RT   "Establishment and characterization of a poorly differentiated lethal
RT   human endometrial carcinoma cell line (NOU-1) with karyotype 46,XX.";
RL   Cancer Genet. Cytogenet. 138:44-49(2002).
//
RX   PubMed=20944090; DOI=10.1126/scitranslmed.3001538;
RA   Dedes K.J., Wetterskog D., Mendes-Pereira A.M., Natrajan R.,
RA   Lambros M.B., Geyer F.C., Vatcheva R., Savage K., Mackay A.,
RA   Lord C.J., Ashworth A., Reis-Filho J.S.;
RT   "PTEN deficiency in endometrioid endometrial adenocarcinomas predicts
RT   sensitivity to PARP inhibitors.";
RL   Sci. Transl. Med. 2:53ra75.1-53ra75.8(2010).
//
RX   PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005;
RA   Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P.,
RA   Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L.,
RA   Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D.,
RA   Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B.,
RA   Liang H.;
RT   "Characterization of human cancer cell lines by reverse-phase protein
RT   arrays.";
RL   Cancer Cell 31:225-239(2017).
//